Switching Early to Camizestrant May Delay Progression: ASCO 2025
Switching to camizestrant upon detection of an ESR1 mutation, before clinical disease progression, may extend progression-free survival (PFS) for patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer, according to results from the Phase III SERENA-6 trial.